MA34897B1 - Formulations d'immunosupresseurs - Google Patents

Formulations d'immunosupresseurs

Info

Publication number
MA34897B1
MA34897B1 MA36170A MA36170A MA34897B1 MA 34897 B1 MA34897 B1 MA 34897B1 MA 36170 A MA36170 A MA 36170A MA 36170 A MA36170 A MA 36170A MA 34897 B1 MA34897 B1 MA 34897B1
Authority
MA
Morocco
Prior art keywords
api
immunosuppressors
formations
compound
solvate
Prior art date
Application number
MA36170A
Other languages
English (en)
Inventor
Philippe Bouillot
Emeric Reynaud
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44022942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34897(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34897B1 publication Critical patent/MA34897B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une composition pharmaceutique à phase solide comprenant un ou plusieurs excipients pharmaceutiquement acceptables et un ingrédient pharmaceutiquement actif (« API ») qui est un composé de formule A1 ou A2, ou un sel, solvate ou hydrate pharmacologiquement acceptable de celui-ci, dans lequel l'API n'est pas exposé à un composé basique.
MA36170A 2011-01-07 2012-01-05 Formulations d'immunosupresseurs MA34897B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11150431 2011-01-07
PCT/EP2012/050151 WO2012093161A1 (fr) 2011-01-07 2012-01-05 Formulations d'immunosuppresseurs

Publications (1)

Publication Number Publication Date
MA34897B1 true MA34897B1 (fr) 2014-02-01

Family

ID=44022942

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36170A MA34897B1 (fr) 2011-01-07 2012-01-05 Formulations d'immunosupresseurs

Country Status (36)

Country Link
US (4) US20130273161A1 (fr)
EP (2) EP3590507A1 (fr)
JP (2) JP6111202B2 (fr)
KR (2) KR102166885B1 (fr)
CN (1) CN103458877B (fr)
AR (2) AR084801A1 (fr)
AU (1) AU2012204835B2 (fr)
BR (1) BR112013017302B1 (fr)
CA (1) CA2823616C (fr)
CL (1) CL2013001979A1 (fr)
CO (1) CO6761402A2 (fr)
CY (1) CY1122182T1 (fr)
DK (1) DK2661261T3 (fr)
EA (1) EA026144B9 (fr)
EC (1) ECSP13012812A (fr)
ES (1) ES2751920T3 (fr)
GT (1) GT201300178A (fr)
HR (1) HRP20191842T1 (fr)
HU (1) HUE045612T2 (fr)
IL (1) IL227094B (fr)
JO (1) JO3619B1 (fr)
LT (1) LT2661261T (fr)
MA (1) MA34897B1 (fr)
MX (2) MX371290B (fr)
MY (1) MY161162A (fr)
PE (1) PE20140216A1 (fr)
PH (1) PH12013501442B1 (fr)
PL (1) PL2661261T3 (fr)
PT (1) PT2661261T (fr)
SG (1) SG191286A1 (fr)
SI (1) SI2661261T1 (fr)
TN (1) TN2013000257A1 (fr)
TW (2) TWI610672B (fr)
UA (1) UA114283C2 (fr)
WO (1) WO2012093161A1 (fr)
ZA (1) ZA201304465B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
EP3129020A1 (fr) * 2014-04-10 2017-02-15 Novartis AG Régime posologique de modulateur s1p à libération immédiate
ES2865451T3 (es) * 2014-04-10 2021-10-15 Novartis Ag Formulación inmunosupresora
WO2016135644A1 (fr) 2015-02-26 2016-09-01 Novartis Ag Traitement de maladie auto-immune chez un patient recevant en outre un bêtabloquant
EP3318259B1 (fr) 2015-07-03 2023-01-11 Astellas Pharma Inc. Composition pharmaceutique stable pour administration par voie orale
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
CA3074043A1 (fr) 2017-09-27 2019-04-04 Novartis Ag Formulation parenterale comprenant du sitomod
EP3687531A1 (fr) 2017-09-29 2020-08-05 Novartis AG Schéma posologique de siponimod
CA3073910A1 (fr) 2017-09-29 2019-04-04 Novartis Ag Schema posologique de siponimod
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
WO2021214717A1 (fr) 2020-04-23 2021-10-28 Novartis Ag Schéma posologique pour l'utilisation de siponimod pour le traitement du syndrome de détresse respiratoire aiguë
WO2023172508A1 (fr) * 2022-03-09 2023-09-14 Isp Investments Llc Composition d'excipient co-traitée
WO2024126409A1 (fr) 2022-12-12 2024-06-20 Synthon B.V. Composition pharmaceutique contenant du siponimod

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3872113A (en) 1972-05-30 1975-03-18 Endo Lab Hydroxy- and acetoxy-phthalaldehydric acid, O-(substituted) oximes
DE69321823T2 (de) 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
EP0771339B1 (fr) 1994-07-12 2003-10-15 BPSI Holdings, Inc. Composition d'enrobage seche constituant une pellicule de protection contre l'humidite, procede d'enrobage de substrats l'utilisant et tablettes pharmaceutiques ainsi enrobees
WO1997024112A1 (fr) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. Preparation a usage externe
MY121470A (en) 1999-05-03 2006-01-28 Ranbaxy Lab Ltd Stable solid pharmaceutical compositions containing enalapril maleate
EP1315735A4 (fr) 2000-08-31 2005-04-06 Merck & Co Inc Derives de phosphates utilises en tant qu'agents immuno-regulateurs
AR041786A1 (es) 2002-03-15 2005-06-01 Novartis Ag Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento
PT1505959E (pt) 2002-05-16 2009-02-05 Novartis Ag Utilização de agentes de ligação do receptor edg em cancro
AU2003277607B2 (en) * 2002-11-07 2009-01-22 Taisho Pharmaceutical Co., Ltd. Base for oral composition and oral composition
PE20130200A1 (es) 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
EP1644367B1 (fr) 2003-05-19 2015-10-14 Novartis AG Compositions et composes immunosuppresseurs
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CL2004001120A1 (es) 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
AU2004271804B2 (en) 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
ES2405404T3 (es) 2003-10-29 2013-05-31 Wyeth Llc Composiciones farmacéuticas de liberación sostenida que comprenden aplindore y sus derivados
AU2005237254B2 (en) 2004-05-03 2010-02-04 Novartis Ag Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
KR20070085465A (ko) 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
EP1688141A1 (fr) 2005-01-31 2006-08-09 elbion AG Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
RU2296999C2 (ru) 2005-03-09 2007-04-10 Алексей Арнольдович Корженевский Способ выявления критериев для проведения адекватной иммунотерапии гнойно-септических заболеваний
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
WO2007048219A2 (fr) 2005-09-09 2007-05-03 Labopharm Inc. Composition medicamenteuse a liberation prolongee
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008072056A1 (fr) 2006-12-14 2008-06-19 Pfizer Limited Utilisation d'inhibiteurs de mtp pour traiter l'obésité au moyen de faibles doses et de doses augmentées
DE102007019417A1 (de) 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
CA2684953C (fr) 2007-05-04 2016-08-09 Novartis Ag Utilisation d'un modulateur des recepteurs s1p
EP3733161A1 (fr) * 2007-10-12 2020-11-04 Novartis AG Compositions comprenant des modulateurs de récepteur de sphingosine 1 (s1p) phosphate
PL2278960T5 (pl) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1
JP2011525189A (ja) 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物
EP2695615A3 (fr) 2008-07-23 2014-04-30 Novartis AG Modulateurs du récepteur de sphingosine 1 phosphate et leur utilisation pour le traitement de l'inflammation musculaire
KR101618906B1 (ko) * 2008-08-18 2016-05-09 노파르티스 아게 말초 신경병증의 치료를 위한 화합물
US20120115840A1 (en) 2008-12-18 2012-05-10 Lech Ciszewski Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid
KR20110101159A (ko) * 2008-12-18 2011-09-15 노파르티스 아게 신규 염
JP2012512884A (ja) * 2008-12-18 2012-06-07 ノバルティス アーゲー １−（４−｛１−［（ｅ）−４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシイミノ］−エチル｝−２−エチル−ベンジル）−アゼチジン−３−カルボン酸の新規の多形相
WO2010070083A1 (fr) 2008-12-19 2010-06-24 Novartis Ag Embout buccal pour un inhalateur
TW201028143A (en) 2008-12-22 2010-08-01 Novartis Ag Dosage regimen for a S1P receptor agonist
JP5657565B2 (ja) 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
NZ598534A (en) 2009-09-29 2014-03-28 Novartis Ag Dosage regimen of an s1p receptor modulator
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
WO2012095853A1 (fr) 2011-01-10 2012-07-19 Novartis Pharma Ag Formulations à libération modifiée comprenant des modulateurs des récepteurs sip
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
BR112015020140A8 (pt) 2013-04-04 2019-11-19 Novartis Ag ácido 1-{4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil}-azetidina-3-carboxílico, seus usos e combinação farmacêutica
ES2865451T3 (es) 2014-04-10 2021-10-15 Novartis Ag Formulación inmunosupresora

Also Published As

Publication number Publication date
CN103458877B (zh) 2016-06-08
KR102166885B1 (ko) 2020-10-19
EA026144B1 (ru) 2017-03-31
JP6111202B2 (ja) 2017-04-05
JO3619B1 (ar) 2020-08-27
MX2013007909A (es) 2013-08-29
ES2751920T3 (es) 2020-04-02
AR084801A1 (es) 2013-06-26
KR20190025727A (ko) 2019-03-11
BR112013017302A2 (pt) 2016-10-25
SG191286A1 (en) 2013-07-31
CO6761402A2 (es) 2013-09-30
TW201609092A (zh) 2016-03-16
PH12013501442A1 (en) 2013-09-09
PT2661261T (pt) 2019-10-25
PE20140216A1 (es) 2014-03-01
CY1122182T1 (el) 2020-11-25
KR101951966B1 (ko) 2019-02-25
EP2661261A1 (fr) 2013-11-13
SI2661261T1 (sl) 2019-11-29
NZ612420A (en) 2015-05-29
PH12013501442B1 (en) 2018-04-20
IL227094B (en) 2019-03-31
JP2014501770A (ja) 2014-01-23
GT201300178A (es) 2014-12-30
TN2013000257A1 (en) 2014-11-10
US20250084034A1 (en) 2025-03-13
WO2012093161A1 (fr) 2012-07-12
DK2661261T3 (da) 2019-10-21
US20130273161A1 (en) 2013-10-17
AU2012204835A1 (en) 2013-08-01
JP2017141248A (ja) 2017-08-17
HRP20191842T1 (hr) 2019-12-27
MX357304B (es) 2018-07-04
EP3590507A1 (fr) 2020-01-08
MY161162A (en) 2017-04-14
CA2823616A1 (fr) 2012-07-12
EA201391018A1 (ru) 2013-11-29
LT2661261T (lt) 2019-10-25
US20200199069A1 (en) 2020-06-25
EP2661261B1 (fr) 2019-07-31
ZA201304465B (en) 2014-02-26
BR112013017302B1 (pt) 2021-12-07
US20220064110A1 (en) 2022-03-03
TWI583380B (zh) 2017-05-21
HUE045612T2 (hu) 2020-01-28
CA2823616C (fr) 2019-01-29
UA114283C2 (uk) 2017-05-25
TW201249438A (en) 2012-12-16
EA026144B9 (ru) 2021-10-26
CL2013001979A1 (es) 2013-11-22
PL2661261T3 (pl) 2020-01-31
AU2012204835B2 (en) 2015-07-09
MX371290B (es) 2020-01-24
US12071402B2 (en) 2024-08-27
KR20140037815A (ko) 2014-03-27
AR124662A2 (es) 2023-04-19
CN103458877A (zh) 2013-12-18
TWI610672B (zh) 2018-01-11
JP6324569B2 (ja) 2018-05-16
ECSP13012812A (es) 2013-09-30

Similar Documents

Publication Publication Date Title
MA34897B1 (fr) Formulations d'immunosupresseurs
EA202191286A1 (ru) Ингибитор 15-pgdh
EP4483882A3 (fr) Nouveaux dérivés de méthylquinazolinone
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MX2010004232A (es) Compuesto de indolina de pirimidilo.
SE0400284D0 (sv) Novel compounds
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
EA201101398A1 (ru) Замещенные пиперидины в качестве антагонистов ccr3
EA201000050A1 (ru) Замещенные бициклолактамные соединения
CY1119357T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν συνδετες υποδοχεων σιγμα
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MY181731A (en) Azole benzene derivative
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
FR2983409B1 (fr) Comprime susceptible de lutter contre le detournement par voie injectable
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
MY199779A (en) Pyrrolopyrimidine compound and use thereof
NO20075482L (no) Propan-1,3-dionderivat og salt derav
MA39983A (fr) Dérivés de carboxamide
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
AR070179A1 (es) DERIVADOS DE PIRIDAZINA, PROCESOS PARA PREPARARLOS, COMPOSICIONES FUNGICIDAS Y FARMACÉUTICAS QUE LOS COMPRENDEN Y SU USO EN MÉTODOS DE PREVENCIoN DE INFESTACIoN DE CULTIVOS Y EN MEDICAMENTOS CONTRA EL CANCER.
SA521421997B1 (ar) مركب 1، 3، 4-أكسا ديازولون ومستحضر صيدلاني
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.